Mr. Brian Firth reports
GEMINA ANNOUNCES EXERCISE OF WARRANTS AND SHARES FOR DEBT ISSUANCE
Gemina Laboratories Ltd. has received
aggregate gross proceeds of $435,000 from the exercise of 966,667 common share purchase
warrants. Each warrant was exercisable at a price of 45 cents to purchase one common share of the
company until July 16, 2024.
The company also announces that it has agreed to issue to certain lenders of the company an
aggregate of 100,000 common shares of the company at an issue price of 40 cents per share in full and
final settlement of financing related expenses owing by the company in the amount of $40,000 related to a 2023 loan. The common shares issued pursuant to the debt
settlement will be subject to a statutory hold period of four months from the date of issuance
under applicable Canadian securities laws, in addition to such other restrictions as may apply under
applicable securities laws of jurisdictions outside Canada.
About Gemina Laboratories Ltd.
Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary
chemistry that powers next-generation testing platforms for a wide range of pathogens that affect
human health and wellness. The company's technology drives testing platforms that are fast, affordable and
accurate, and easily self-administered. The company's development pipeline includes platforms for the rapid
testing of COVID-19, influenza and other viruses.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.